21 research outputs found
Recommended from our members
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs.
Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a promising approach for current drug discovery. Although structure-based drug design of biased agonists remains challenging even with an abundance of GPCR crystal structures, we present an approach for translating GPCR structural data into β-arrestin-biased ligands for aminergic GPCRs. We identified specific amino acid-ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 2 (EL2) responsible for Gi/o and β-arrestin signaling, respectively, and targeted those residues to develop biased ligands. For these ligands, we found that bias is conserved at other aminergic GPCRs that retain similar residues at TM5 and EL2. Our approach provides a template for generating arrestin-biased ligands by modifying predicted ligand interactions that block TM5 interactions and promote EL2 interactions. This strategy may facilitate the structure-guided design of arrestin-biased ligands at other GPCRs, including polypharmacological biased ligands
Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies
A set of molecules that advanced
into exploratory animal toxicology
studies (two species) was examined to determine what properties contributed
to success in these safety studies. Compounds were rigorously evaluated
across numerous safety end points and classified as “pass”
if a suitable in vivo therapeutic index (TI) was achieved for advancement
into regulatory toxicology studies. The most predictive end point
contributing to compound survival was a predicted human efficacious
concentration (<i>C</i><sub>eff</sub>) of ≤250 nM
(total drug) and ≤40 nM (free drug). This trend held across
a wide range of CNS modes of action, encompassing targets such as
enzymes, G-protein-coupled receptors, ion channels, and transporters